SG11202003441VA - PYRIMIDINE ΤΒΚ/ΙΚΚε INHIBITOR COMPOUNDS AND USES THEREOF - Google Patents
PYRIMIDINE ΤΒΚ/ΙΚΚε INHIBITOR COMPOUNDS AND USES THEREOFInfo
- Publication number
- SG11202003441VA SG11202003441VA SG11202003441VA SG11202003441VA SG11202003441VA SG 11202003441V A SG11202003441V A SG 11202003441VA SG 11202003441V A SG11202003441V A SG 11202003441VA SG 11202003441V A SG11202003441V A SG 11202003441VA SG 11202003441V A SG11202003441V A SG 11202003441VA
- Authority
- SG
- Singapore
- Prior art keywords
- τβκ
- pyrimidine
- inhibitor compounds
- ικκε
- ικκε inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573255P | 2017-10-17 | 2017-10-17 | |
| PCT/US2018/056192 WO2019079375A1 (en) | 2017-10-17 | 2018-10-17 | PYRIMIDINE ΤΒΚ/ΙΚΚε INHIBITOR COMPOUNDS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003441VA true SG11202003441VA (en) | 2020-05-28 |
Family
ID=64110186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003441VA SG11202003441VA (en) | 2017-10-17 | 2018-10-17 | PYRIMIDINE ΤΒΚ/ΙΚΚε INHIBITOR COMPOUNDS AND USES THEREOF |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11440899B2 (en) |
| EP (1) | EP3697773A1 (en) |
| JP (1) | JP7284161B2 (en) |
| KR (1) | KR20200071756A (en) |
| CN (1) | CN111247134A (en) |
| AU (1) | AU2018352701A1 (en) |
| BR (1) | BR112020007549A2 (en) |
| CA (1) | CA3078583A1 (en) |
| IL (1) | IL273892A (en) |
| MX (1) | MX2020003487A (en) |
| RU (1) | RU2020115295A (en) |
| SG (1) | SG11202003441VA (en) |
| TW (1) | TWI802605B (en) |
| WO (1) | WO2019079375A1 (en) |
| ZA (1) | ZA202002825B (en) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050203092A1 (en) * | 2000-08-08 | 2005-09-15 | Benjamin Elfrida R. | 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods |
| ATE398109T1 (en) | 2000-08-08 | 2008-07-15 | Ortho Mcneil Pharm Inc | 4-PYRIMIDINAMININE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS |
| US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| EP1678147B1 (en) * | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| US20090221581A1 (en) | 2005-05-25 | 2009-09-03 | Philipp Wabnitz | Methods of treating pain |
| FR2911139A1 (en) | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | New 2,4-diaminopyrimidine derivatives useful for treating inflammatory diseases, diabetes or cancer |
| JP5611826B2 (en) | 2007-09-04 | 2014-10-22 | ザ スクリプス リサーチ インスティテュート | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| KR20120114224A (en) * | 2009-10-12 | 2012-10-16 | 마이렉시스 인코포레이티드 | Amino-pyrimidine compounds as inhibitors of tbkl and/or ikk epsilon |
| GB201012105D0 (en) | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
| CA2832919A1 (en) * | 2011-04-12 | 2012-10-18 | Ryan C. Holcomb | Compounds, compositions, and therapeutic uses thereof |
| DE102011112978A1 (en) | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | benzonitrile derivatives |
| WO2013117285A1 (en) | 2012-02-09 | 2013-08-15 | Merck Patent Gmbh | Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors |
| WO2013175415A1 (en) * | 2012-05-23 | 2013-11-28 | Piramal Enterprises Limited | Substituted pyrimidine compounds and uses thereof |
| TW201418243A (en) * | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group |
| GB201303109D0 (en) * | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
| ES2881195T3 (en) * | 2014-09-26 | 2021-11-29 | Gilead Sciences Inc | Aminotriazine Derivatives Useful As TANK-Binding Kinase Inhibitor Compounds |
| CA2985859A1 (en) * | 2015-06-29 | 2017-01-05 | Merck Patent Gmbh | Tbk/ikk.epsilon. inhibitor compounds and uses thereof |
| CN106928216A (en) * | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | Compound, Preparation Method And The Use with ERK kinase inhibiting activities |
| TWI802604B (en) * | 2017-10-17 | 2023-05-21 | 德商默克專利有限公司 | PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF |
-
2018
- 2018-10-17 CA CA3078583A patent/CA3078583A1/en active Pending
- 2018-10-17 CN CN201880067976.7A patent/CN111247134A/en active Pending
- 2018-10-17 WO PCT/US2018/056192 patent/WO2019079375A1/en unknown
- 2018-10-17 JP JP2020521570A patent/JP7284161B2/en active Active
- 2018-10-17 TW TW107136568A patent/TWI802605B/en active
- 2018-10-17 EP EP18797387.0A patent/EP3697773A1/en active Pending
- 2018-10-17 RU RU2020115295A patent/RU2020115295A/en unknown
- 2018-10-17 MX MX2020003487A patent/MX2020003487A/en unknown
- 2018-10-17 US US16/756,954 patent/US11440899B2/en active Active
- 2018-10-17 KR KR1020207013748A patent/KR20200071756A/en not_active Application Discontinuation
- 2018-10-17 AU AU2018352701A patent/AU2018352701A1/en not_active Abandoned
- 2018-10-17 BR BR112020007549-3A patent/BR112020007549A2/en unknown
- 2018-10-17 SG SG11202003441VA patent/SG11202003441VA/en unknown
-
2020
- 2020-04-07 IL IL273892A patent/IL273892A/en unknown
- 2020-05-15 ZA ZA2020/02825A patent/ZA202002825B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019079375A1 (en) | 2019-04-25 |
| JP7284161B2 (en) | 2023-05-30 |
| US11440899B2 (en) | 2022-09-13 |
| ZA202002825B (en) | 2023-05-31 |
| MX2020003487A (en) | 2020-07-22 |
| RU2020115295A (en) | 2021-11-18 |
| KR20200071756A (en) | 2020-06-19 |
| BR112020007549A2 (en) | 2020-09-24 |
| IL273892A (en) | 2020-05-31 |
| JP2020537661A (en) | 2020-12-24 |
| EP3697773A1 (en) | 2020-08-26 |
| RU2020115295A3 (en) | 2021-11-18 |
| CN111247134A (en) | 2020-06-05 |
| US20210214339A1 (en) | 2021-07-15 |
| TW201922729A (en) | 2019-06-16 |
| AU2018352701A1 (en) | 2020-06-04 |
| CA3078583A1 (en) | 2019-04-25 |
| TWI802605B (en) | 2023-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273236A (en) | Pyrazolopyrimidinone compounds and uses thereof | |
| HK1251547A1 (en) | Pyrimidine or pyridopyridone compound and application thereof | |
| GB201708652D0 (en) | Novel compounds and uses | |
| IL269711A (en) | Ask1 inhibitor compounds and uses thereof | |
| IL259150B (en) | Pyrimidine derivative and use thereof | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| GB201714745D0 (en) | New compounds and uses | |
| IL254974B (en) | Crystalline fgfr4 inhibitor compound and uses thereof | |
| GB201714740D0 (en) | New compounds and uses | |
| IL262400A (en) | Erbb inhibitors and uses thereof | |
| GB201714734D0 (en) | New compounds and uses | |
| IL292488B1 (en) | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds | |
| SG11202004361SA (en) | Quinazolinone compound and application thereof | |
| SG11202003407VA (en) | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | |
| GB201714736D0 (en) | New compounds and uses | |
| IL292482B2 (en) | Azaindolylpyridone and diazaindolylpyridone compounds | |
| GB201712110D0 (en) | New compounds and uses | |
| GB201700404D0 (en) | Compounds and composistions | |
| ZA202002825B (en) | Pyrimidine τβκ/ικκε inhibitor compounds and uses thereof | |
| GB201720092D0 (en) | New Compounds and uses | |
| GB201719327D0 (en) | New compounds and uses | |
| GB201719233D0 (en) | New compounds and uses | |
| GB201714743D0 (en) | New compounds and uses | |
| GB201705201D0 (en) | Novel compounds and their use as kinase inhibitors |